A new discovery could pave the way for more effective cancer treatment by helping certain drugs work better inside the body.

Scientists have found a surprising new way to make certain cancer drugs work dramatically better – by helping them get inside ...

This Novo Nordisk drug is a combination of semaglutide with ... It is expected to become the first PROTAC ...

These are molecules — first described in a paper co-authored by Yale University researcher Craig Crews, founder of the first PROTAC-focused drug developer — that exploit naturally-occurring ...

The two companies will also share costs and profits from the drug, which will start a phase 3 programme next year. The buy-in is another endorsement of Arvinas' PROTAC drugs, bifunctional ...

Arvinas' ARV-102 reduced LRRK2 protein in a Phase 1 trial, showing promising safety and pharmacodynamic outcomes for ...

However, drug resistance often occurs when tumors shift to alternative ... However, due to its strong cardiotoxicity, bufalin has limited translational potential. A PROTAC is a heterobifunctional ...

The money will go toward work at the Center for Innovative Drug Discovery (CIDD), a joint venture between ... An innovative method they will develop is the Proteolysis-Targeting Chimeras (PROTAC) ...

“Dr. McHardy is an acknowledged expert in the area of drug design and medicinal chemistry," said John ... First, we have several developing programs in the area of protein degradation using PROTAC ...